TYK2 and psoriasis vulgaris: Deucravacitinib, a U.S. Food and Drug Administration-approved tyrosine kinase 2 (TYK2) inhibitor, has shown robust efficacy in Phase III trials for moderate-to-severe plaque psoriasis, with a favorable safety profile.